Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene therapy hope for PKU: first human safety trial launches

NCT ID NCT06061614

First seen Mar 02, 2026 · Last updated May 24, 2026 · Updated 11 times

Summary

This early-stage study tests a single intravenous dose of NGGT002, a gene therapy for adults with phenylketonuria (PKU), a genetic disorder that prevents the breakdown of the amino acid phenylalanine. Fifteen participants will be monitored for safety and changes in blood phenylalanine levels for up to 5 years. The goal is to see if the treatment is safe and can help control the disease, though lifelong management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHENYLKETONURIAS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Bengbu Medical College

    RECRUITING

    Bengbu, Anhui, 233000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.